BMJ Open  Current provision of myelopathy education in medical schools in the UK: protocol for a national medical student survey

Oliver Mowforth,1 Benjamin Davies,1 Max Stewart,2 Sam Smith,2 Alice Willison,3 Shahzaid Ahmed,2 Michelle Starkey,4 Iwan Sadler,4 Ellen Sarewitz,4 Sybil Stacpoole,5 Mark Kotter1,6

ABSTRACT

Introduction Degenerative cervical myelopathy (DCM) is a common, disabling and progressive neurological condition triggered by chronic compression of the cervical spinal cord by surrounding degenerative changes. Early diagnosis and specialist management are essential to reduce disability, yet time to diagnosis is typically prolonged. Lack of sufficient representation of DCM in undergraduate and postgraduate medical curricula may contribute to the poor recognition of DCM by non-specialist doctors in clinical practice. In this study, our objective, therefore, is to assess DCM teaching provision in medical schools throughout the UK and to assess the impact of teaching on the DCM knowledge of UK medical students.

Methods and analysis A 19-item questionnaire capturing data on medical student demographics, myelopathy teaching and myelopathy knowledge was designed. Ethical approval was granted by the Psychology Research Ethics Committee, University of Cambridge. An online survey was hosted on Myelopathy.org, an international myelopathy charity. Students studying at a UK medical school are eligible for inclusion. The survey is advertised nationally through university social media pages, university email bulletins and the national student network of Myelopathy.org. Advertisements are scheduled monthly over a 12-month recruitment period. Participation is incentivised by entering consenting participants of completed surveys to an Amazon voucher prize draw. Responses are anonymised using participant-chosen unique identifier codes. A participant information sheet followed by an explicit survey question captures participant informed consent. Regular updates on the progress of the study will be published on Myelopathy.org.

Ethics and Dissemination Ethical approval for the study was granted by the Psychology Research Ethics Committee, University of Cambridge (PRE.2018.099). The findings of the study described in this protocol, and all other related work, will be submitted for publication in a peer-reviewed journal and will be presented at scientific conferences.

INTRODUCTION

Degenerative cervical myelopathy (DCM) is a common neurological condition of symptomatic cervical spinal cord compression due to degenerative changes of the spine (figure 1).1 DCM is the most common cause of spinal cord impairment in adults worldwide, with an estimated prevalence of up to 5% in the over 40s.1–3

Substantial improvements in the care of patients with DCM could be realised today without any additional scientific understanding of the condition.1 Patients with DCM almost universally experience diagnostic delays. For example, one study demonstrated that on average it took 2 years and five clinic appointments before the diagnosis was made.4 Improvement in diagnosis is therefore a key target that would provide immediate reductions in disability.5

Initially, patients with DCM are commonly seen by primary care, emergency and medical physicians.6 7 These non-specialist triage points appear key to earlier diagnosis, yet DCM features poorly in medical curricula.8 This risks non-specialist doctors being poorly equipped to detect DCM.

The current focus and makeup of DCM medical education are unclear. Our recent
evaluation of undergraduate and postgraduate medical curricula identified deficiencies in DCM representation, however, collectively this did not correlate with student performance in multiple-choice question banks.8

The aim of this study is to describe the teaching of DCM in UK medical schools and to assess the influence on medical student knowledge of DCM. Ultimately, the aim is to identify both training and knowledge gaps to inform guidance on DCM education in order to address the burden and impact of delayed diagnosis. We hypothesise that knowledge and awareness among medical professionals are related to their specific medical education on DCM.

METHODS AND ANALYSIS

Study partners

Myelopathy.org

Myelopathy.org is an international cervical myelopathy charity, which aims to improve health and wellbeing in DCM.9 This study forms part of a wider project to evaluate DCM education and awareness among medical professionals in the UK and develop focused and effective interventions to improve this. This includes our recent gap analysis of key medical resources and knowledge at each stage of the primary care training pathway8 and an educational article on DCM for non-specialist medical professionals, commissioned by the British Medical Journal (figure 2).1 The charity is focused on understanding how medical education can be improved as one possible strategy to address the current problems of delayed, missed and underdiagnosis.1

Student Society of Myelopathy.org

The foundations of professional knowledge begin with students’ formative experiences at medical school. Therefore, the Student Society of Myelopathy.org was established in 2018 with the aim of improving DCM engagement and awareness among medical students. The society remains in its infancy but has hosted a series of educational talks at the University of Cambridge; established national medical student essay and research prizes; designed and

Figure 1  Typical MRI scan from patient with degenerative cervical myelopathy showing spinal cord compression and multilevel degenerative changes.

Degenerative cervical myelopathy

Benjamin M Davies academic clinical fellow and specialist registrar neurosurgery, Oliver D Mowforth medical student,1 Emma K Smith specialist registrar general practice,2 Mark RN Kotter clinician scientist1 and consultant neurosurgeon1

1 Academic neurosurgery unit, Department of Clinical Neurosurgery, University of Cambridge, Cambridge, UK; 2 School of General Practice, NHS Health Education East of England, UK

Figure 2  Degenerative cervical myelopathy educational article commissioned by the British Medical Journal. Reproduced with permission from British Medical Journal.
Study design
An electronic survey was agreed to be the most efficient way to simultaneously assess teaching, perceptions of teaching and current knowledge and to efficiently reach students from all UK medical schools. Part 1 of the survey was designed to capture data on basic demographic characteristics and teaching on DCM in UK medical schools. Part 2 was designed to capture data on knowledge and awareness of fundamental DCM facts including prevalence, symptoms, diagnostic imaging modalities and surgical effectiveness in addition to appreciation of important current challenges such as prolonged time to diagnosis and poor patient quality of life. Part 2 was designed to capture participant’s perception of their DCM knowledge. These questions were considered to be a reasonable balance of capturing sufficient data while maintaining an acceptably short survey completion time of approximately 5 min.

The study management team comprised representation from second year to final year students from multiple UK medical schools. The team comprised an academic neurosurgical registrar (BD) and an academic neurosurgical consultant (MK), both with special clinical and academic interests in DCM, and an academic consultant neurologist (S Stacpoole) who is a neuroscience teaching fellow and neuroscience course organiser at the University of Cambridge. Importantly, this is a student-motivated, student-led project with supervision, oversight and mentorship at all stages of the study from a team of senior researchers.

The survey was iteratively refined among the study management group until section 1 was felt to capture sufficient information on current DCM teaching provision in UK medical schools. Similarly, section 2 was refined until it was felt to evaluate fundamental DCM facts at a level sufficient for a non-specialist but qualified doctor to appropriately suspect, investigate, diagnose and redirect care in DCM. In total, a 19-item questionnaire was developed (figure 3).

Survey development closely aligns with the Association for Medical Education in Europe (AMEE) seven-step guide to medical education survey development: (1) literature review, (2) focus group establishment, (3) synthesis of literature review/focus group, (4) item development, (5) expert validation, (6) feedback and expert validation and (7) piloting, with the exception that a quantitative gap analysis was performed in the place of a literature review due to the lack of research on DCM medical education at the time of study design. Nonetheless, planning for a systematic review of similar medical education surveys in other diseases is underway.

Survey piloting
The survey was piloted in January 2019 by a group of 20 medical students at the University of Cambridge. These students were not directly involved in the design of the study. Data were inspected to identify any inconsistencies, ambiguities and problematic survey items. No issues were identified. Students in the pilot group were contacted to ask whether they had encountered any difficulties, areas of uncertainty or suggestions for improving the survey. Students reported the survey to be acceptable on both desktop and mobile devices. Informal cognitive interviews of five students revealed that survey items were interpreted by students as intended by the study team, without ambiguity. No further alterations were therefore made. No formal statistical data analysis was conducted at the pilot stage.

Survey administration
To maximise reach across the UK, the survey was hosted on Qualtrics survey software (Provo, Utah, USA), a professional online survey platform. Qualtrics survey software includes both desktop and mobile-compatible versions, maximising convenience for participants.

The survey comprises two pages. The first page acts as a frontpage consisting of a participant information sheet and a question capturing informed consent. The second page is the main survey page. It comprises 19 questions over a single page to minimise the number of clicks required for participants to complete the survey.

Survey dissemination
A network of Myelopathy.org student representatives was recruited, with representation of students from 25 different medical schools across the UK. Some but not all were also representatives for the Society of British Neurological Surgeons and Neurology and Neurosurgery Student Interest Group (NANSIG). A standard advertisement devised by the protocol development team and approved by the research ethics committee is used for all advertising (figure 4). Representatives from all medical schools are sent monthly reminder emails to disseminate adverts at their institution over a 12-month period from February 2019 to January 2020. There was no difference in the timing of reminder emails between different medical schools. Although prompted to advertise monthly, the final decision on frequency of advertising at each institution is left to the discretion of representatives, guided by local rules.

On completion of the survey participants are invited to leave an email address in a separate Google Forms survey to be entered into a prize draw to win one of five £10 Amazon vouchers. The prize draw was agreed by the study management group and approved by the research ethics committee. The rationale was that prizes of this value may encourage participation without providing an inappropriate incentive to participate.

The survey is advertised in social media groups and on social media pages for relevant student groups and societies at universities across the UK. For example, Facebook groups of surgical, neurosurgical, neurological and other medical student societies were approached. In addition, university mailing lists and email bulletins are being
Myelopathy Student Survey

First Question. Consent: I have read the participant information sheet and consent to my survey response being used in this study (yes/no).

Survey Part 1: Teaching

- Which medical school do you study at?
  (dropdown selection of all UK medical schools, including other category)
- Preclinical or clinical?
  (dropdown selection of preclinical or clinical)
- Which year of medical school?
  (dropdown selection: year 1; year 2; year 3; year 4; year 5; year 6; other)
- What is your planned/most likely career specialty?
  (free entry)
- Have you heard of degenerative cervical myelopathy (also known as cervical spondylotic myelopathy)?
  (dropdown selection: yes; no)
- Have you had any teaching on cervical myelopathy from your medical school?
  (dropdown selection: yes; no)
- What is the total duration of your cervical myelopathy teaching?
  (dropdown selection: 0 mins; 15 mins; 30 mins; 1 hour; 2 hours; >2 hours)
- What form did the teaching take?
  (dropdown selection: lecture; seminar; ward-based teaching; e-learning; other; N/A)
- How much private study have you done on cervical myelopathy?
  (dropdown selection: 0 mins; 15 minutes; 30 minutes; 1 hour; 2 hours; >2 hours)

Survey Part 2: Knowledge

For many of the following questions there is often not necessarily a right or wrong and we are often more interested in your perception.

- How would you rate your overall knowledge of cervical myelopathy?
  (dropdown selection: excellent, very good, average, poor, very poor)
- What do you estimate is the prevalence of cervical myelopathy in the over 40s?
  (dropdown selection: 0.01%; 0.1%; 1%; 5%; 10%; 50%)
- Which do you think is the best imaging modality to diagnose myelopathy? (4 or 5 choices)
  (dropdown selection: MRI; CT; X-ray; myelography; ultrasound)
- What do you think the average time to diagnosis is from first presentation? (5 choices)
  (dropdown selection: 1 week; 1 month; 1 year; 2 years; 5 years)
- On average, how many consultations do you think there are before a patient is diagnosed?
  (dropdown selection 1; 2; 5; 10; 20)
- Do you think time to diagnosis is likely important for long-term prognosis?
  (dropdown selection: yes; no)
- What effect do you think surgery is likely to have on a patient's symptoms?
  (dropdown selection: improve; stabilise; worsen)
- Which of these symptoms might be present in cervical myelopathy?
  (dummy gait; neck pain/stiffness; falls; imbalance; loss of bowel control; loss of urinary control; erectile dysfunction; paraesthesia; limb weakness; limb numbness; limb pain; loss of dexterity)
- Please rank these conditions from worst to best in terms of your estimate of patient quality of life?
  (dropdown selection: cancer; cervical myelopathy; diabetes; depression; heart failure)
- How would you most like to learn about cervical myelopathy in the future?
  (dropdown selection: lecture; seminar; private study; online e-learning material; not interested)

Figure 3 Final survey design. Reproduced with permission from Myelopathy.org.

used, where appropriate, in accordance with local rules. Adverts are also placed in the monthly NANSIG newsletter, emailed out to medical student subscribers across the UK. The survey link is also hosted on the Student Society of Myelopathy.org webpage and Facebook page.

Eligibility and representation

All UK medical students are eligible to complete the survey. We aim to secure representation of all UK medical schools.

Consent and confidentiality

A patient information sheet (PIS) including a question capturing informed consent forms the survey frontpage (figure 5). The PIS emphasises the rational, purpose, study aims and the voluntariness of participation. By necessity, the background information on DCM in the PIS is minimal to avoid compromising the DCM knowledge-based questions in the survey. A page block is used to separate the front and main survey pages.

Participants assign themselves a unique identifier based on a defined combination of characters from their mother’s maiden name, the street they grew up on and their mobile phone number; this ensures anonymity and confidentiality while allowing the possibility of linking together future surveys from the same participant.
Data security
All data are stored exclusively on the secure, online Qualtrics platform until closure of the survey. Thereafter, survey data will be extracted directly from the Qualtrics platform into a password-encrypted Excel spreadsheet (Microsoft, California, USA) on a password-protected computer. Only the immediate research team will be granted access to this on a need-to-access basis. After completion of data analysis, all data that are no longer required will be deleted. No participant-identifiable data will be collected or stored at any point.

Figure 4  A standard advertisement devised by the protocol development team and approved by the research ethics committee is being used for all survey advertising. Reproduced with permission from Myelopathy.org.

Figure 5  Survey frontpage including patient information sheet and capturing of informed consent. Reproduced with permission from Myelopathy.org.
Statistical analysis
Data will be analysed in Microsoft Excel and using statistical software.

Relationships between duration of DCM teaching, duration of private study on DCM and student perception of their DCM knowledge and objective performance in the DCM knowledge-based questions will be assessed. Differences in performance on the knowledge-based questions will be compared between groups based on medical school, year of medical school, duration of teaching, format of teaching, duration of private study, prior self-reported awareness of DCM, self-rating of DCM knowledge and between groups of medical students wishing to pursue neurological/neurosurgical career specialties and those who do not.

Due to all items in the survey being mandatory, we anticipate that missing data will be minimal, however we will conduct a missing data analysis as necessary. It is not expected the data will be suitable for imputation, thus we will compare demographics to establish any selection bias caused by the exclusion of missing values. We will perform analysis on all collected values. The survey findings will be presented using descriptive statistics. Inferential statistical tests may be used to consider the relationship between knowledge and educational provision. Distribution testing will be performed. Appropriate statistical methods will be selected based on the class and distribution of the data; it is anticipated data will be non-parametric, and as measures are recorded on an ordinal or categorical basis, will therefore be compared using tests such as \( \chi^2 \) or Kruksall-Wallis tests.

Patient and public involvement
Patients were involved in the conception, design, development and conduct of this study. A DCM Patient and Public Engagement Day hosted at the University of Cambridge was captured by Cambridge TV in a documentary. During this day, a focus group of patients were involved in the conception, design, development and conduct of this study. A DCM Patient and Public Engagement Day hosted at the University of Cambridge was captured by Cambridge TV in a dissertation. During this day, a focus group of patients were involved in the conception, design, development and conduct of this study. A DCM Patient and Public Engagement Day hosted at the University of Cambridge was captured by Cambridge TV in a dissertation. During this day, a focus group of patients were involved in the conception, design, development and conduct of this study.

Discussions
This is the first study to describe the DCM education at medical schools nationally. Medical students are recruited to an online survey, including an assessment of their DCM knowledge and their personal DCM learning experience. By comparison of learning experience and knowledge, and also comparison between medical schools, it is anticipated both the presence or absence of a knowledge gap can be evaluated, and the more successful teaching formats are identified. This will be used to inform Myelopathy.org education recommendations.

Why assess DCM education?
DCM is a devastating condition with one of the poorest quality of life scores of any chronic disease. Symptoms include loss of manual dexterity, gait impairment, limb paraesthesia, limb weakness, limb stiffness, bladder and bowel disturbance, neck pain and neck stiffness. The full spectrum of symptoms and the natural history of DCM are poorly appreciated, yet it remains clear that the condition poses a substantial burden on the physical and mental health of people with DCM and their supporters. There is a broad differential for DCM symptoms and poor consensus on what the most common DCM symptoms are. In addition, an increasing number of less well-described symptoms such as dysaesthetic sensory symptoms, chest tightness and headache are being reported. Neurological examination findings include upper motor neuron signs in the upper and lower limbs: spasticity and hyperreflexia in addition to weakness.

The latest international guidelines recommend surgical decompression as the only evidence-based management for patients with moderate to severe, or progressive DCM. Surgery is also a management option in patients with mild DCM. Importantly, surgery can halt progression of the condition but is ineffective at reversing existing damage. Therefore, the traditional medical dogma that prevention is better than cure holds as strongly as ever in DCM: time is spine.

Scientific advances are sorely needed to improve therapeutic options and ultimately to cure disabled patients with DCM. However, while research into the neurobiology of DCM and neural regeneration, such as the RECIDE-Myelopathy and CSM-PROTECT trials offer hope for the future, even the most optimistic scientist would concede that tangible benefits for patients arising from these technologies remain on the horizon: one systematic review reported average duration of knowledge translation of 17 years from research to practice.

Therefore, pragmatic approaches are required to improve outcomes for today’s patients with DCM. One such approach entails addressing the substantial problem of diagnostic delays, which is expected to improve outcomes in this progressive condition. One method of instituting this may be through better education. Indeed, a phenomenon of ‘neurophobia’ is well described among medical students and non-specialist
Additionally, evidence from our recent gap analysis suggests poor representation of DCM in medical curricula. These factors may point to a knowledge gap in DCM medical education.

**Benefits of a medical student survey**

Assessing teaching and knowledge among medical students is a pragmatic and initial step to evaluate a knowledge gap. Medical school is the foundation of all medical professionals’ education and is especially important for instilling basic knowledge of important areas of medicine that may fall outside a doctor’s future field of specialisation. It is likely that this is particularly pertinent for knowledge that this not later core (ie, built on or refined) during specialisation. For this purpose, a survey of medical students is best placed to simultaneously assess knowledge, while reporting on the current provision of DCM teaching and perceptions of it. Moreover, the survey itself may help to prime an audience to support a subsequent intervention, or at the very least raise awareness.

Urgent improvements in outcomes for patients with DCM are needed. Earlier diagnosis would improve outcomes based on current treatments. This study aims to evaluate DCM education and knowledge, and explore their relationship, among medical students. It is hoped this will inform educational interventions that may offer the greatest chance of shaping the non-specialist doctor’s diagnosis of DCM tomorrow.

**LIMITATIONS**

Online surveys are an effective method of reaching students from diverse medical schools. In addition, digital collection of data offers a secure and seamless stream, facilitating data analysis. However, their limitation is in understanding how representative the findings are.

In order to mitigate this, a number of different dissemination approaches are being employed. This includes the appointment of local representatives at each UK medical school, the use social media posts, society mailing lists, society newsletters, medical school email bulletins, medical school newsletters and also the use of prizes as an incentive. Additionally, the capture of participant demographics will help to measure the sample characteristics.

The engagement with open surveys often involves some predefined interest. It is possible therefore a selection bias towards students interested in neurosciences is more likely and results would be considered as a best-case scenario. While there is a risk of overlooking or underestimating the magnitude of a knowledge gap given the outlined benefits of this methodology, this is an accepted risk. Whatever the relationship between DCM teaching and knowledge turns out to be, it will be instructive with regards to the overall objective of identifying ways of improving DCM diagnosis.

We acknowledge that the wording of the survey item ‘Do you think time to diagnosis is important for long-term prognosis?’ could be perceived as leading and would have been better phrased in a more neutral format such as ‘How important is time to diagnosis for long-term prognosis?’ We will monitor the performance of this item closely in our analysis.

**ETHICS AND DISSEMINATION**

Ethical approval for the study was granted by the Psychology Research Ethics Committee, University of Cambridge (PRE.2018.099). Insurance cover was arranged via the University of Cambridge (HVS/2018/2366). The findings of the study described in this protocol, and all other related work, will be submitted for publication in a peer-reviewed journal and will be presented at scientific conferences.

**Author affiliations**

1 Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
2 School of Clinical Medicine, University of Cambridge, Cambridge, UK
3 Ninewells Hospital and Medical School, University of Dundee, Dundee, UK
4 Myelopathy.org, Cambridge, UK
5 Neurology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK
6 Anne McLaren Laboratory for Regenerative Medicine, Wellcome Trust-Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK

**Acknowledgements**

The authors are grateful to all the patients who have inspired this study, most especially at the University of Cambridge Patient and Public Engagement Day. In addition, the authors would like to thank the Student Society of Myelopathy.org and NANSIG medical student representatives for their assistance in disseminating the research survey.

**Contributors**

OM, BD, IS, ES, SStacpoole and MK were involved in the conceptualisation and design of this study. OM wrote the first draft of the manuscript. OM, BD, MS, SSmith, AW, SA, MS, IS, ES, SStacpoole and MK reviewed and approved the final manuscript.

**Funding**

Research in the MK’s laboratory is supported by a core support grant from the Wellcome Trust and MRC to the Wellcome Trust–Medical Research Council Cambridge Stem Cell Institute. MK is supported by an NIHR Clinician Scientist Award and BD is supported by an NIHR Clinical Doctoral Research Fellowship.

**Disclaimer**

This report is independent research arising from a Clinician Scientist Award, CS-2015-15-023, supported by the National Institute for Health Research. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

**Competing interests**

OM, BD, MS, SSmith, AW, SA, MS, IS, ES and MK have voluntary roles at Myelopathy.org, an international DCM charity.

**Patient and public involvement**

Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

**Patient consent for publication**

Not required.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

**ORCID iD**

Oliver Mowforth http://orcid.org/0000-0001-6788-745X
REFERENCES

1. Davies BM, Mowforth OD, Smith EK, et al. Degenerative cervical myelopathy. BMJ 2018;360:k186.
2. Kovalova I, Kerkovius M, Kadanka Z, et al. Prevalence and imaging characteristics of nonmyelopathic and myelopathic spondylotic cervical cord compression. Spine 2016;41:1908–16.
3. Nouri A, Tetreault L, Singh A, et al. Degenerative cervical myelopathy: epidemiology, genetics, and pathogenesis. Spine 2015;40:E675–93.
4. Behrbalk E, Salame K, Regev GJ, et al. Delayed diagnosis of cervical spondylotic myelopathy by primary care physicians. Neurosurg Focus 2013;35:E1.
5. Cates JR, Soriano MM. Cervical spondylotic myelopathy. J Manipulative Physiol Ther 1995;18:471–5.
6. Mowforth OD, Davies BM, Kotter MR. “I am not delusional!” Sensory dysaesthesia secondary to degenerative cervical myelopathy. BMJ Case Rep 2012;e229033.
7. Radcliff KE, Curry EP, Trima R, et al. High incidence of undiagnosed cervical myelopathy in patients with hip fracture compared with controls. J Orthop Trauma 2016;30:189–93.
8. Waqar M, Wilcock J, Garner J, et al. Quantitative analysis of medical students’ and physicians’ knowledge of degenerative cervical myelopathy. BMJ Open 2020;10:e029455.
9. The Lancet Neurology. A focus on patient outcomes in cervical myelopathy. Lancet Neurol 2019;18:615.
10. Artoni AR, La Rochelle JS, Dezee KJ, et al. Developing questionnaires for educational research: AMEE guide No. 87. Med Teach 2014;36:663–74.
11. Roberts E. Elemental ideas: cervical spondylotic myelopathy. Available: http://www.myelopathy.org/the-csm-documentary.html
12. Oh T, Lafage R, Lafage V, et al. Comparing quality of life in cervical spondylotic myelopathy with other chronic debilitating diseases using the short forim survey 36-Health survey. World Neurosurg 2017;106:699–706.
13. Arnold JG. The clinical manifestations of spondylochondrosis (spondylosis) of the cervical spine. Ann Surg 1955;141:872–89.
14. Brain WR, Northfield D, Wilkinson M. The neurological manifestations of cervical spondylolisthesis. Brain 1952;75:167–221.
15. Baddhiwala JH, Wilson JR. The natural history of degenerative cervical myelopathy. Neurosurg Clin N Am 2018;29:21–32.
16. St. Clair S, Bell GR. Natural history of cervical spondylotic myelopathy. Semin Spine Surg 2007;19:2–5.
17. Stoffman MR, Roberts MS, King JT. Cervical spondylotic myelopathy, depression, and anxiety: a cohort analysis of 89 patients. Neurosurgery 2005;57:307–13. discussion 307–313.
18. Mowforth OD, Davies BM, Kotter MR. Quality of life among informal caregivers of patients with degenerative cervical myelopathy: cross-sectional questionnaire study. Interact J Med Res 2019;8:e12381.
19. Tracy JA, Bartleson JD. Cervical spondylotic myelopathy. Neurologist 2010;16:176–87.
20. Kobayashi H, Ikikuchi S-iichi, Otani K, et al. Development of a self-administered questionnaire to screen patients for cervical myelopathy. BMC Musculoskelet Disord 2010;11:268.
21. Schrot RJ, Mathew JS, Li Y, et al. Headache relief after anterior cervical discectomy: post hoc analysis of a randomized investigational device exemption trial: clinical article. J Neurosurg Spine 2014;21:217–22.
22. Davies BM, Munro CF, Kotter MR. A novel insight into the challenges of diagnosing degenerative cervical myelopathy using web-based symptom Checkers. Spine 2016;41:1908–16.
23. Fehlings MG, Tetreault LA, Riew KD, et al. A clinical practice guideline for the management of patients with degenerative cervical myelopathy: recommendations for patients with mild, moderate, and severe disease and Nonmyelopathic patients with evidence of cord compression. Spine 2015;40:E1222–8.
24. Fehlings MG, Ibrahim A, Tetreault L, et al. A global perspective on the outcomes of surgical decompression in patients with cervical spondylotic myelopathy: results from the prospective multicenter AOOSpine international study on 479 patients. Spine 2015;40:E1222–8.
25. Fehlings MG, Wilson JR, Kojjar B, et al. Efficacy and safety of surgical decompression in patients with cervical spondylotic myelopathy: results of the AOOSpine North America prospective multicenter study. J Bone Joint Surg Am 2013;95:1651–8.
26. Mowforth OD, Davies BM, Goh S, et al. Research inefficiency in degenerative cervical myelopathy: findings of a systematic review on research activity over the past 20 years. Global Spine J 2020;10:476–85.
27. Davies BM, Khan DZ, Mowforth OD, et al. RE-CODE DCM (REsearch Objectives and Common Data Elements for Degenerative Cervical Myelopathy): A Consensus Process to Improve Research Efficiency in DCM, Through Establishment of a Standardized Dataset for Clinical Research and the Definition of the Research Priorities. Global Spine J 2019;9:655–66.
28. Chlouverakis P, Ryan S, Karadimas SK, et al. Cervical spondylotic myelopathy: the clinical phenomenon and the current pathobiology of an increasingly prevalent and devastating disorder. Neuroscientist 2013;19:409–21.
29. Fehlings MG, Wilson Jr, Karadimas SK, et al. Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial. Spine 2013;38:658–75.
30. Kato S, Fehlings M. Degenerative cervical myelopathy. Curr Rev Musculoskelet Med 2016;9:263–71.
31. Mounis ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med 2011;104:510–20.
32. Pokrzywko-Dragan A, Mottershead J, Attkin G. Attitudes towards neurology among medical undergraduates. Neurol Neurochir Pol 2012;46:581–73.
33. Shiels L, Majmundar P, et al. Medical student attitudes and educational interventions to prevent neurophobia: a longitudinal study. BMC Med Educ 2017;17:225.
34. Conway S, Tynan J, Conway S, et al. Efficacy and safety of an increasingly prevalent and devastating disorder. Familial spastic paraparesis. Neurology 2015;84:388–96.
35. Fehlings MG, Wilson JR, Karadimas SK, et al. Clinical evaluation of a neuroprotective drug in patients with cervical spondylotic myelopathy undergoing surgical treatment: design and rationale for the CSM-Protect trial. Spine 2013;38:658–75.
36. Edwards PJ, Roberts I, Clarke MJ, et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev 2009;3:MR00008.